Matching articles for "Vowst"

Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023;  (Issue 1677)
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection (CDI) in adults. Vowst is the first orally administered microbiota-based treatment to be approved for this indication. A rectally-administered live fecal microbiota-based suspension (Rebyota) was approved in 2022 for the same indication. Neither product is approved for acute treatment of CDI.
Med Lett Drugs Ther. 2023 May 29;65(1677):81-2 | Show Full IntroductionHide Full Introduction